Evaluation and Modeling with the Therapeutic Effects Group
Members
Stagiaire
UCBL
Maîtresse de conférences - praticienne hospitalière
UCBL
Tel: 04 72 11 94 07
Stagiaire
UCBL
Maître de conférences - praticien hospitalier
UCBL
Tel: 33 04 72 32 34 87
Professeur des universités - médecin généraliste
UCBL
Tel: 04 78 74 18 18
Maîtresse de conférences
UCBL
Tel: 33 04 78 78 57 83
Professeure des universités - médecin généraliste
UCBL
Tel: 04 78 77 72 86
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 72 44 81 42
Assistant hospitalier universitaire
UCBL
Doctorant
UCBL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 16 80 99
Doctorante
autre
Tel: 04 72 44 81 42
Praticien hospitalier
HCL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier émérite
UCBL
Stagiaire
HCL
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 27 85 77 32
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 78 86 33 01
Maîtresse de conférences - praticienne hospitalière
UCBL
Stagiaire
HCL
Maître de conférences - praticien hospitalier
UCBL
Tel: 04 72 11 94 20
Doctorant
HCL
Tel: 04 72 44 81 42
Doctorante
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 12 94 37
Professeur d'université - praticien hospitalier émérite
UCBL
Doctorante
UCBL
Tel: 04 72 44 81 42
Stagiaire
HCL
EMET presentation
The EMET team brings together doctors, pharmacists and research professors specializing in the evaluation and use of drug and non-drug therapies, around a single project built on two axes:
- the evaluation of therapies in clinical trials or observational studies;
- the construction of explanatory and predictive models, to better understand and therefore predict the effect of therapies, simulate their impacts at the individual and population level, and improve the innovation paradigm.
The EMET team is therefore part of two major dynamics in therapy: analysis of the level of evidence and precision medicine.
The fields of application are cardiovascular and metabolic diseases, primary care medicine, rare pediatric diseases (including genetic and autoimmune diseases), oncology and infectious diseases.
EMET members implement approaches using different mathematical models: direct comparison and network meta-analysis, pharmacokinetic/pharmacodynamic analysis, Bayesian networks and machine learning.
Education
The EMET team is specially involved in the teaching of pharmacology and therapeutics and the modeling of the treatment effect through the coordination of the Masters 2 Clinical Evaluation (EC) and Pharmacology modeling and clinical trials (PHAME), Interpretation of Therapeutic Trials (IET), Training of investigators in clinical drug trials (FIEC) and Training of clinical research assistants and clinical study technicians (FARCTEC). Teacher-researchers are also involved in the first (pharmacology), second (pharmacology / therapeutics, pharmacy) and third cycles (general medicine, pediatrics, internal medicine) in health training courses.
Society involvement
The members of the EMET team through their work and their interactions with the other components of the LBBE, National societies, governmental (HAS) or international (EMA) agencies, and the Hospices Civils de Lyon, are invested in current societal issues: rationalization of the use of health product resources, research ethics, gender equality, rationality of approaches in analyzing the diversity of human populations.
Publications
Display of 121 to 150 publications on 256 in total
A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients
Medical Microbiology and Immunology . 204 ( 4 ) : 493-504
Journal article
see the publicationIdiopathic inflammatory myopathies and the lung
European Respiratory Review . 24 ( 136 ) : 216-238
Journal article
see the publicationUptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study
British medical journal . 350 : h1088
DOI: 10.1136/bmj.h1088
Journal article
see the publicationSubcutaneous administration of levetiracetam in geriatrics
Revue Neurologique . 171 : 398-399
Journal article
see the publicationA pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells-using rifampicin as an example
European Journal of Clinical Pharmacology . 71 ( 3 ) : 313-9
Journal article
see the publicationQuantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure
Clinical Pharmacokinetics . 54 : 319-20
Journal article
see the publicationModel-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children
AAPS Journal . 17 ( 5 ) : 1157-67
Journal article
see the publicationPopulation modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs
Antimicrobial Agents and Chemotherapy . 59 ( 9 ) : 5181-5189
DOI: 10.1128/AAC.00462-15
Journal article
see the publicationInfluence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients
Antimicrobial Agents and Chemotherapy . 59 ( 6 ) : 2986-94
DOI: 10.1128/AAC.04132-14
Journal article
see the publicationA Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification
Clinical Pharmacokinetics . 54 : 1245-58
Journal article
see the publicationExposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus
Antimicrobial Agents and Chemotherapy . 58 ( 9 ) : 5306-5314
DOI: 10.1128/AAC.02574-14
Journal article
see the publicationImpact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis
Journal of Cystic Fibrosis . 13 ( 6 ) : 667-673
Journal article
see the publicationConsistency of safety profile of new oral anticoagulants in patients with renal failure
Journal of Thrombosis and Haemostasis . 12 ( 2 ) : 337-43
DOI: 10.1111/jth.12486
Journal article
see the publicationCharacteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study
Seminars in Arthritis and Rheumatism . 43 ( 5 ) : 681--688
Journal article
see the publicationThe clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome
Autoimmunity Reviews . 13 : 883-91
Journal article
see the publicationThe clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome
Autoimmunity Reviews . 13 ( 9 ) : 883-891
Journal article
see the publicationRisk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis
Autoimmunity Reviews . 13 : 595-608
Journal article
see the publicationConsistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation
PLoS ONE . 9 ( 3 ) : e91398
Journal article
see the publicationMutations in CECR1 associated with a neutrophil signature in peripheral blood
Pediatric Rheumatology . 12 : 44
Journal article
see the publicationComparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population
Journal of the Royal Society Interface . 11 ( 100 ) : 20140867
Journal article
see the publicationThe effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
Orphanet Journal of Rare Diseases . 9 : 142
Journal article
see the publicationEffects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence?
Diabetes & Metabolism . 40 : 169-75
Journal article
see the publicationTranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease
Journal of Thrombosis and Haemostasis . 12 : 1494-502
DOI: 10.1111/jth.12654
Journal article
see the publicationImproving risk prediction performance for a better guidelines application
Journal of Hypertension . 32 : 1192-1193
Journal article
see the publicationThe Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy
Current Pharmaceutical Design . 20 : 6191-6206
Journal article
see the publicationImpact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis
British Journal of Clinical Pharmacology . 78 ( 1 ) : 24-32
DOI: 10.1111/bcp.12289
Journal article
see the publicationCardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies: Systematic Review and Meta-analysis
JAMA Ophthalmology . 132 ( 11 ) : 1317-26
Journal article
see the publicationGuidelines for Managing High Blood Pressure
Journal of the American Medical Association . 312 ( 3 ) : 293-294
Journal article
see the publicationMultivariate meta-analysis using individual participant data
Research Synthesis Methods . 6 ( 2 ) : 157-174
DOI: 10.1002/jrsm.1129
Journal article
see the publicationDeterminants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study
Drugs & aging . 31 : 601-9
Journal article
see the publication
You also, comment on this article